US Patent

US7855211 — Protein kinase inhibitors

Method of Use · Assigned to Eli Lilly and Co · Expires 2031-09-28 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

Eli Lilly and Co's patent US 7855211 protects a compound of formula (I) or its pharmaceutically acceptable salt for treating cell proliferative diseases.

USPTO Abstract

The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2135 — Verzenio
U-1981 — Verzenio
U-2135 — Verzenio
U-2135 — Verzenio

Patent Metadata

Patent number
US7855211
Jurisdiction
US
Classification
Method of Use
Expires
2031-09-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.